<?xml version="1.0" ?>
<document id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0">
  <chunk id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c0" text="Proteomic fingerprinting in HIV/HCV co- infection reveals serum biomarkers for the diagnosis of fibrosis staging on behalf of the Canadian Co-Infection Cohort (CTN222) Â¶ 1 Program in Infectious Diseases and Immunity in Global">
    <entity charOffset="152-158" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c0.e0" ontology_id="CHEBI_34935" text="Cohort" type="chemical"/>
  </chunk>
  <chunk id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1" text="Hepatic complications of hepatitis C virus (HCV), including fibrosis and cirrhosis are accelerated in human immunodeficiency virus (HIV)-infected individuals. Although, liver biopsy remains the gold standard for staging HCV-associated liver disease, this test can result in serious complications and is subject to sampling errors. These challenges have prompted a search for non-invasive methods for liver fibrosis staging. To this end, we compared serum proteome profiles at different stages of fibrosis in HIV/HCV co-and HCV mono-infected patients using surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS).">
    <entity charOffset="25-34" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e0" ontology_id="DOID_2237" text="hepatitis" type="disease"/>
    <entity charOffset="25-36" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e1" ontology_id="DOID_1883" text="hepatitis C" type="disease"/>
    <entity charOffset="73-82" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e2" ontology_id="DOID_5082" text="cirrhosis" type="disease"/>
    <entity charOffset="194-198" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e3" ontology_id="CHEBI_29287" text="gold" type="chemical"/>
    <pair e1="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e0" e2="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e3" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.p0" relation="true"/>
    <pair e1="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e1" e2="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e3" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.p1" relation="true"/>
    <pair e1="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e2" e2="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.e3" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c1.p2" relation="true"/>
  </chunk>
  <chunk id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c2" text="Sera from 83 HIV/HCV co-and 68 HCV mono-infected subjects in 4 stages of fibrosis were tested. Sera were fractionated, randomly applied to protein chip arrays (IMAC, CM10 and H50) and spectra were generated at low and high laser intensities.">
    <entity charOffset="139-146" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c2.e0" ontology_id="CHEBI_16541" text="protein" type="chemical"/>
  </chunk>
  <chunk id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c3" text="Sixteen biomarkers achieved a p value &lt; 0.01 (ROC values &gt; 0.75 or &lt; 0.25) predictive of fibrosis status in co-infected individuals and 14 in mono infected subjects. Five of these candidate biomarkers contributed to both mono-and co-infected subjects. Candidate diagnostic algorithms were created to distinguish between non-fibrotic and fibrotic individuals using a panel of 4 biomarker peaks.">
    <entity charOffset="377-386" id="0a01f5cf1c5cdc2711bcef74315dc54a6e143df0.c3.e0" ontology_id="CHEBI_59163" text="biomarker" type="chemical"/>
  </chunk>
</document>
